CSL Seqirus Enhances Availability of Influenza Vaccine in the U.S. Market After Successful Production Campaign#USA#Influenza_vaccine#Holly_Springs#CSL_Seqirus#Vaccine_Supply
CSL Seqirus Enhances Availability of Influenza Vaccine in the U.S. Market After Successful Production Campaign
CSL Seqirus announced the increased availability of influenza vaccines in the U.S. following the successful completion of their manufacturing campaign for the 2026/27 season, crucial amid reported supply challenges.
third-news.com
September 29, 2026 at 2:04 PM
CSL Seqirus Enhances Availability of Influenza Vaccine in the U.S. Market After Successful Production Campaign#USA#Influenza_vaccine#Holly_Springs#CSL_Seqirus#Vaccine_Supply
Novavax Launches Phase 3 Trial for Combined COVID-19 and Influenza Vaccine#USA#Novavax#Gaithersburg#COVID-19_vaccine#Influenza_vaccine
Novavax Launches Phase 3 Trial for Combined COVID-19 and Influenza Vaccine
Novavax has initiated a Phase 3 trial for its COVID-19-influenza combination and stand-alone influenza vaccines, targeting older adults.
third-news.com
December 10, 2024 at 1:30 PM
Novavax Launches Phase 3 Trial for Combined COVID-19 and Influenza Vaccine#USA#Novavax#Gaithersburg#COVID-19_vaccine#Influenza_vaccine
Novavax Unveils Promising Results for H5N1 Vaccine Candidate in Preclinical Trials#USA#Novavax#Gaithersburg#Influenza_vaccine#Nanoparticle
Novavax Unveils Promising Results for H5N1 Vaccine Candidate in Preclinical Trials
Novavax's H5N1 avian flu vaccine candidate shows strong immune response in preclinical studies, indicating potential for pandemic preparedness.
third-news.com
July 24, 2025 at 12:27 PM
Novavax Unveils Promising Results for H5N1 Vaccine Candidate in Preclinical Trials#USA#Novavax#Gaithersburg#Influenza_vaccine#Nanoparticle
Sino Biological Accelerates Influenza Vaccine Development for Northern Hemisphere 2026-2027#USA#Houston#Influenza_vaccine#Sino_Biological#WHO_Recommendations
Sino Biological Accelerates Influenza Vaccine Development for Northern Hemisphere 2026-2027
Sino Biological has unveiled new antigens aimed at enhancing the development of the 2026-2027 influenza vaccine, responding to the WHO's recent guidelines.
third-news.com
March 5, 2026 at 6:38 PM
Sino Biological Accelerates Influenza Vaccine Development for Northern Hemisphere 2026-2027#USA#Houston#Influenza_vaccine#Sino_Biological#WHO_Recommendations
Sino Biological Unveils Cutting-Edge Influenza Vaccine Antigens for 2026-2027#USA#Houston#Influenza_vaccine#Sino_Biological#WHO_Recommendations
Sino Biological Unveils Cutting-Edge Influenza Vaccine Antigens for 2026-2027
Sino Biological is set to enhance influenza vaccine development with new antigens for the northern hemisphere strains for 2026-2027, following WHO's recommendations.
third-news.com
March 4, 2026 at 7:22 PM
Sino Biological Unveils Cutting-Edge Influenza Vaccine Antigens for 2026-2027#USA#Houston#Influenza_vaccine#Sino_Biological#WHO_Recommendations
Sino Biological Introduces New Antigens for 2026-2027 Northern Hemisphere Influenza Vaccine#USA#Houston#Influenza_vaccine#WHO#Sino_Biological
Sino Biological Introduces New Antigens for 2026-2027 Northern Hemisphere Influenza Vaccine
Sino Biological has launched new antigens targeted for the 2026-2027 Northern Hemisphere flu vaccine, addressing recent WHO recommendations amid evolving strains.
third-news.com
March 4, 2026 at 7:21 PM
Sino Biological Introduces New Antigens for 2026-2027 Northern Hemisphere Influenza Vaccine#USA#Houston#Influenza_vaccine#WHO#Sino_Biological
Sino Biological Unveils Key Antigens for Upcoming Influenza Vaccine Development#USA#Houston#Influenza_vaccine#Sino_Biological#H3N2_Strain
Sino Biological Unveils Key Antigens for Upcoming Influenza Vaccine Development
Sino Biological has introduced new antigens for the 2026-2027 Northern Hemisphere influenza vaccines in response to WHO's recent recommendations.
third-news.com
March 4, 2026 at 3:00 AM
Sino Biological Unveils Key Antigens for Upcoming Influenza Vaccine Development#USA#Houston#Influenza_vaccine#Sino_Biological#H3N2_Strain
Sino Biological Accelerates Vaccine Innovation for 2026-2027 Northern Hemisphere Influenza Strains#United_States#Houston#Influenza_vaccine#Sino_Biological#WHO_Recommendations
Sino Biological Accelerates Vaccine Innovation for 2026-2027 Northern Hemisphere Influenza Strains
Sino Biological is launching antigens for the 2026-2027 flu vaccine as WHO updates its strain recommendations, addressing the rise of new influenza variants.
third-news.com
March 4, 2026 at 2:08 AM
Sino Biological Accelerates Vaccine Innovation for 2026-2027 Northern Hemisphere Influenza Strains#United_States#Houston#Influenza_vaccine#Sino_Biological#WHO_Recommendations
Innovative Nasal Spray Influenza Vaccine from DIFF Biotech Gains Approval for Clinical Trials#China#Hangzhou#Influenza_vaccine#DIFF_Biotech#DIFF-flu
Innovative Nasal Spray Influenza Vaccine from DIFF Biotech Gains Approval for Clinical Trials
DIFF Biotech's nasal spray influenza vaccine, DIFF-flu, has received approval for clinical trials in China, showcasing new safety features and innovation.
third-news.com
February 9, 2026 at 1:18 PM
Innovative Nasal Spray Influenza Vaccine from DIFF Biotech Gains Approval for Clinical Trials#China#Hangzhou#Influenza_vaccine#DIFF_Biotech#DIFF-flu
Influenza Prevention Drugs: A Growing Popularity Alongside Vaccines#Japan#Tokyo#Influenza_vaccine#Fit_Clinic#Tamiflu
Influenza Prevention Drugs: A Growing Popularity Alongside Vaccines
A recent survey sheds light on how many people are combining influenza prevention drugs with vaccines to protect their families against the flu.
third-news.com
November 26, 2025 at 5:31 AM
Influenza Prevention Drugs: A Growing Popularity Alongside Vaccines#Japan#Tokyo#Influenza_vaccine#Fit_Clinic#Tamiflu
Advancing Vaccination: Apriori Bio and A*STAR Join Forces on Influenza Research#United_States#Cambridge#Influenza_vaccine#Apriori_Bio#A*STAR_IDL
Advancing Vaccination: Apriori Bio and A*STAR Join Forces on Influenza Research
Apriori Bio and A*STAR IDL are joining efforts to innovate next-gen vaccines using cutting-edge RNA technology, aiming to boost global health security against influenza.
third-news.com
November 18, 2025 at 8:11 AM
Advancing Vaccination: Apriori Bio and A*STAR Join Forces on Influenza Research#United_States#Cambridge#Influenza_vaccine#Apriori_Bio#A*STAR_IDL
Why is Influenza Spreading Earlier This Year? Insights and Recommendations#Japan#Tokyo#Health_Insights#Influenza_vaccine#Hidden_Influenza
Why is Influenza Spreading Earlier This Year? Insights and Recommendations
This article explores the early spread of influenza and effective prevention measures based on recent studies and expert insights.
third-news.com
October 29, 2025 at 11:17 PM
Why is Influenza Spreading Earlier This Year? Insights and Recommendations#Japan#Tokyo#Health_Insights#Influenza_vaccine#Hidden_Influenza
SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#adjuvant_technology
SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission
SK bioscience has submitted an IND application for a Phase 1/2 clinical trial of a new adjuvanted influenza vaccine, aiming to enhance protective efficacy for vulnerable populations.
third-news.com
July 17, 2025 at 11:08 AM
SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#adjuvant_technology
Novavax Unveils Positive Results for Combined COVID-19 and Influenza Vaccine in Phase 3 Trial#United_States#Novavax#Gaithersburg#COVID-19_vaccine#Influenza_vaccine
Novavax Unveils Positive Results for Combined COVID-19 and Influenza Vaccine in Phase 3 Trial
Novavax has reported promising initial results for its combined COVID-19-Influenza vaccine and a stand-alone flu vaccine. Both candidates showed strong immune responses in a Phase 3 trial.
third-news.com
June 11, 2025 at 11:16 AM
Novavax Unveils Positive Results for Combined COVID-19 and Influenza Vaccine in Phase 3 Trial#United_States#Novavax#Gaithersburg#COVID-19_vaccine#Influenza_vaccine
SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#SKYCellflu
SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets
SK bioscience has commenced the export of its SKYCellflu influenza vaccine to Southern Hemisphere markets, enhancing global vaccine access and production stability.
third-news.com
March 12, 2025 at 12:15 PM
SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#SKYCellflu
Projected Growth in Global Influenza Vaccine Market Surpassing USD 14 Billion by 2032#None#Market_Insights#Influenza_vaccine#Vaccine_Companies
Projected Growth in Global Influenza Vaccine Market Surpassing USD 14 Billion by 2032
The influenza vaccine market is set to exceed USD 14 billion by 2032, driven by rising flu incidents and vaccination efforts. This report highlights crucial insights.
third-news.com
February 20, 2025 at 10:34 PM
Projected Growth in Global Influenza Vaccine Market Surpassing USD 14 Billion by 2032#None#Market_Insights#Influenza_vaccine#Vaccine_Companies
DIOSynVax Establishes Advisory Board to Enhance NextGen Influenza Vaccine Development#USA#Cambridge#Influenza_vaccine#DIOSynVax#Bird_Flu_Vaccine
DIOSynVax Establishes Advisory Board to Enhance NextGen Influenza Vaccine Development
DIOSynVax announces the formation of a new advisory board aimed at accelerating the clinical development of NextGen influenza vaccines, including bird flu.
third-news.com
January 9, 2025 at 4:09 PM
DIOSynVax Establishes Advisory Board to Enhance NextGen Influenza Vaccine Development#USA#Cambridge#Influenza_vaccine#DIOSynVax#Bird_Flu_Vaccine
DIOSynVax Announces New Advisory Board to Boost Influenza Vaccine Development#USA#Cambridge#Influenza_vaccine#Bird_Flu#DIOSynVax
DIOSynVax Announces New Advisory Board to Boost Influenza Vaccine Development
DIOSynVax unveils its new advisory board and innovative influenza vaccine portfolio, enhancing efforts against upcoming pandemics.
third-news.com
January 8, 2025 at 7:31 PM
DIOSynVax Announces New Advisory Board to Boost Influenza Vaccine Development#USA#Cambridge#Influenza_vaccine#Bird_Flu#DIOSynVax